| Quality Life Services - Grove City | |
| 400 Hillcrest Avenue, Grove City, Pennsylvania 16127 | |
| (724) 458-9501 | |
| Name | Quality Life Services - Grove City |
|---|---|
| Location | 400 Hillcrest Avenue, Grove City, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 109 |
| Occupancy Rate | 66.88% |
| Medicare ID (CCN) | 395593 |
| Legal Business Name | Trinity Living Center, Lp |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1215702097 |
| Organization Name | QUALITY LIFE SERVICES - GROVE CITY, LLC |
| Doing Business As | QUALITY LIFE SERVICES - GROVE CITY |
| Address | 400 Hillcrest Ave, Grove City, PA 16127 |
| Phone Number | 724-458-9501 |
News Archive
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 can be detected in the urine and blood and is generally present at low levels in healthy individuals.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
VASCOVID, a new European project, will develop a platform that uses near-infrared light to monitor microvascular health of COVID-19 patients and assist clinicians in delivering customized treatments.
› Verified 2 days ago
| NPI Number | 1679565147 |
| Organization Name | GROVE CITY MEDICAL CENTER |
| Address | 631 N Broad Street Ext, Grove City, PA 16127 |
| Phone Number | 724-458-5442 |
News Archive
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 can be detected in the urine and blood and is generally present at low levels in healthy individuals.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
VASCOVID, a new European project, will develop a platform that uses near-infrared light to monitor microvascular health of COVID-19 patients and assist clinicians in delivering customized treatments.
› Verified 2 days ago
| NPI Number | 1740718477 |
| Organization Name | TRANSITIONAL CARE CENTER LP |
| Address | 631 N Broad Street Ext, Grove City, PA 16127 |
| Phone Number | 724-458-5442 |
News Archive
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 can be detected in the urine and blood and is generally present at low levels in healthy individuals.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
VASCOVID, a new European project, will develop a platform that uses near-infrared light to monitor microvascular health of COVID-19 patients and assist clinicians in delivering customized treatments.
› Verified 2 days ago
| NPI Number | 1760475289 |
| Organization Name | TRINITY LIVING CENTER, LP |
| Address | 400 Hillcrest Ave, Grove City, PA 16127 |
| Phone Number | 724-431-0770 |
News Archive
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 can be detected in the urine and blood and is generally present at low levels in healthy individuals.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
VASCOVID, a new European project, will develop a platform that uses near-infrared light to monitor microvascular health of COVID-19 patients and assist clinicians in delivering customized treatments.
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 can be detected in the urine and blood and is generally present at low levels in healthy individuals.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
VASCOVID, a new European project, will develop a platform that uses near-infrared light to monitor microvascular health of COVID-19 patients and assist clinicians in delivering customized treatments.
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.73 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.23 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 55.8 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.37 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.38 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 8.64 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.19 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 74.19 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 24.91 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 68.93 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.85 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 12.9 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 22.84 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.69 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.39 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 82.23 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 29.69 | 82.93 |
News Archive
A molecule in cells that shuts down the expression of genes might be a promising target for new drugs designed to treat the most frequent and lethal form of brain cancer, according to a new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A critical biomarker of kidney disease may help predict clear cell kidney cancer - the most common form of kidney cancer - years before clinical diagnosis. Kidney-injury-molecule-1 can be detected in the urine and blood and is generally present at low levels in healthy individuals.
Almost from the start of the current COVID-19 pandemic, it has become clear that individuals suffering from other medical conditions like diabetes, cardiovascular disease, and lung disease are far more likely to contract the infection and to have a poorer outcome.
VASCOVID, a new European project, will develop a platform that uses near-infrared light to monitor microvascular health of COVID-19 patients and assist clinicians in delivering customized treatments.
› Verified 2 days ago
Quality Life Services - Grove City Location: 400 Hillcrest Avenue, Grove City, Pennsylvania 16127 Phone: (724) 458-9501 | |